BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6072 related articles for article (PubMed ID: 20620267)

  • 1. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.
    Fraguas D; Merchán-Naranjo J; Laita P; Parellada M; Moreno D; Ruiz-Sancho A; Cifuentes A; Giráldez M; Arango C
    J Clin Psychiatry; 2008 Jul; 69(7):1166-75. PubMed ID: 18588363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
    Lee SY; Park MH; Patkar AA; Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics.
    O'Donoghue B; Schäfer MR; Becker J; Papageorgiou K; Amminger GP
    Early Interv Psychiatry; 2014 Aug; 8(3):276-80. PubMed ID: 23968390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008559. PubMed ID: 28791693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
    Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
    Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness of web-based programs on the reduction of childhood obesity in school-aged children: A systematic review.
    Antwi F; Fazylova N; Garcon MC; Lopez L; Rubiano R; Slyer JT
    JBI Libr Syst Rev; 2012; 10(42 Suppl):1-14. PubMed ID: 27820152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study.
    Baeza I; Vigo L; de la Serna E; Calvo-Escalona R; Merchán-Naranjo J; Rodríguez-Latorre P; Arango C; Castro-Fornieles J
    Eur Child Adolesc Psychiatry; 2017 Jan; 26(1):35-46. PubMed ID: 27209421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prescription of olanzapine in children and adolescent psychiatric patients].
    Frémaux T; Reymann JM; Chevreuil C; Bentué-Ferrer D
    Encephale; 2007; 33(2):188-96. PubMed ID: 17675914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting.
    Pozzi M; Pisano S; Marano G; Carnovale C; Bravaccio C; Rafaniello C; Capuano A; Rossi F; Rizzo R; Bernardini R; Nobile M; Molteni M; Clementi E; Biganzoli E; Radice S
    J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):133-140. PubMed ID: 30452281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and safety profile of risperidone in a sample of children and adolescents.
    Margari L; Matera E; Craig F; Petruzzelli MG; Palmieri VO; Pastore A; Margari F
    Int Clin Psychopharmacol; 2013 Jul; 28(4):177-83. PubMed ID: 23689836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.
    Toren P; Ratner S; Laor N; Weizman A
    Drug Saf; 2004; 27(14):1135-56. PubMed ID: 15554747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients.
    Arango C; Giráldez M; Merchán-Naranjo J; Baeza I; Castro-Fornieles J; Alda JA; Martínez-Cantarero C; Moreno C; de Andrés P; Cuerda C; de la Serna E; Correll CU; Fraguas D; Parellada M
    J Am Acad Child Adolesc Psychiatry; 2014 Nov; 53(11):1179-90,1190.e1-4. PubMed ID: 25440308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
    Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
    Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course.
    Gebhardt S; Haberhausen M; Heinzel-Gutenbrunner M; Gebhardt N; Remschmidt H; Krieg JC; Hebebrand J; Theisen FM
    J Psychiatr Res; 2009 Mar; 43(6):620-6. PubMed ID: 19110264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
    Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
    Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 304.